Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
26
09
2022
accepted:
17
03
2023
revised:
26
04
2023
medline:
28
4
2023
pubmed:
15
4
2023
entrez:
14
4
2023
Statut:
epublish
Résumé
The control of onchocerciasis currently relies on annual distribution of single dose ivermectin. Because ivermectin has minimal effects on the adult parasite, mass drug administration (MDA) campaigns against onchocerciasis require at least 15 years of annual uninterrupted ivermectin distribution. Mathematical models have predicted that short-term disruption of MDA (as was seen during COVID-19) could impacted the microfilaridermia prevalence depending on the pre-control endemicity and the histories of treatment, requiring corrective measures (such as biannual MDA) to mitigate the effect on onchocerciasis elimination. Field evidence supporting this prediction, however, has yet to be gathered. This study aimed to assess the impact of ~2 years disruption of MDA on onchocerciasis transmission indicators. A cross-sectional survey was carried out in 2021 in seven villages of Bafia and Ndikinimeki, two health districts located in the Centre Region, Cameroon, where MDA has been ongoing for two decades, but interrupted in 2020 as a response to the COVID-19 pandemic. Volunteers aged 5 years and above were enrolled for clinical and parasitological examinations for onchocerciasis. Data were compared with pre-COVID-19 prevalence and intensity of infection from the same communities to measure changes over time. A total of 504 volunteers (50.3% males), aged 5-99 years (Median: 38; IQR: 15-54) was enrolled in the two health districts. The overall prevalence of microfilaridermia in 2021 was similar in Ndikinimeki health district (12.4%; 95% CI: 9.7-15.6) and Bafia health district (15.1%; 95% CI: 11.1-19.8) (p-value = 0.16). Microfilaridermia prevalences were either similar between 2018 and 2021 in the communities of Ndikinimeki health district (19.3% vs 12.8% (p = 0.057) for Kiboum 1; and 23.7% vs 21.4% (p = 0.814) for Kiboum 2), or higher in 2019 compared to 2021 in the communities of Bafia health district (33.3% vs 20.0% (p = 0.035) for Biatsota). The mean microfilarial densities in these communities dropped from 5.89 (95% CI: 4.77-7.28) mf/ss to 2.4 (95% CI: 1.68-3.45) mf/ss (p-value < 0.0001), and from 4.81 (95% CI: 2.77-8.31) mf/ss to 4.13 (95% CI: 2.49-6.86) mf/ss (p-value < 0.02) in Bafia and Ndikinimeki health districts, respectively. Community Microfilarial Load (CMFL) dropped from 1.08-1.33 mf/ss in 2019 to 0.052-0.288 mf/ss in 2021 in Bafia health district while remaining stable in the Ndikinimeki health district. The continued decline in prevalence and CMFL observed ~2 years after MDA disruption is consistent with mathematical predictions (ONCHOSIM) and shows that additional efforts and resources are not needed to mitigate the effects of short-term MDA disruption in highly endemic settings prior to intervention with long treatment histories.
Sections du résumé
BACKGROUND
The control of onchocerciasis currently relies on annual distribution of single dose ivermectin. Because ivermectin has minimal effects on the adult parasite, mass drug administration (MDA) campaigns against onchocerciasis require at least 15 years of annual uninterrupted ivermectin distribution. Mathematical models have predicted that short-term disruption of MDA (as was seen during COVID-19) could impacted the microfilaridermia prevalence depending on the pre-control endemicity and the histories of treatment, requiring corrective measures (such as biannual MDA) to mitigate the effect on onchocerciasis elimination. Field evidence supporting this prediction, however, has yet to be gathered. This study aimed to assess the impact of ~2 years disruption of MDA on onchocerciasis transmission indicators.
METHODOLOGY
A cross-sectional survey was carried out in 2021 in seven villages of Bafia and Ndikinimeki, two health districts located in the Centre Region, Cameroon, where MDA has been ongoing for two decades, but interrupted in 2020 as a response to the COVID-19 pandemic. Volunteers aged 5 years and above were enrolled for clinical and parasitological examinations for onchocerciasis. Data were compared with pre-COVID-19 prevalence and intensity of infection from the same communities to measure changes over time.
PRINCIPAL FINDINGS
A total of 504 volunteers (50.3% males), aged 5-99 years (Median: 38; IQR: 15-54) was enrolled in the two health districts. The overall prevalence of microfilaridermia in 2021 was similar in Ndikinimeki health district (12.4%; 95% CI: 9.7-15.6) and Bafia health district (15.1%; 95% CI: 11.1-19.8) (p-value = 0.16). Microfilaridermia prevalences were either similar between 2018 and 2021 in the communities of Ndikinimeki health district (19.3% vs 12.8% (p = 0.057) for Kiboum 1; and 23.7% vs 21.4% (p = 0.814) for Kiboum 2), or higher in 2019 compared to 2021 in the communities of Bafia health district (33.3% vs 20.0% (p = 0.035) for Biatsota). The mean microfilarial densities in these communities dropped from 5.89 (95% CI: 4.77-7.28) mf/ss to 2.4 (95% CI: 1.68-3.45) mf/ss (p-value < 0.0001), and from 4.81 (95% CI: 2.77-8.31) mf/ss to 4.13 (95% CI: 2.49-6.86) mf/ss (p-value < 0.02) in Bafia and Ndikinimeki health districts, respectively. Community Microfilarial Load (CMFL) dropped from 1.08-1.33 mf/ss in 2019 to 0.052-0.288 mf/ss in 2021 in Bafia health district while remaining stable in the Ndikinimeki health district.
CONCLUSION/SIGNIFICANCE
The continued decline in prevalence and CMFL observed ~2 years after MDA disruption is consistent with mathematical predictions (ONCHOSIM) and shows that additional efforts and resources are not needed to mitigate the effects of short-term MDA disruption in highly endemic settings prior to intervention with long treatment histories.
Identifiants
pubmed: 37058547
doi: 10.1371/journal.pntd.0011250
pii: PNTD-D-22-01232
pmc: PMC10132555
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011250Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors declared that no competing interests exist.
Références
Med Trop (Mars). 1978 Jan-Feb;38(1):43-51
pubmed: 723550
Emerg Med J. 2020 Jul;37(7):411
pubmed: 32447306
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:13-7
pubmed: 18718148
Trans R Soc Trop Med Hyg. 2021 Mar 6;115(3):269-280
pubmed: 33515042
Infect Dis Poverty. 2016 Jun 27;5(1):66
pubmed: 27349645
Anesth Analg. 2020 Jul;131(1):86-92
pubmed: 32243287
Ann Trop Med Parasitol. 2002 Mar;96 Suppl 1:S41-58
pubmed: 12081250
Acta Leiden. 1990;59(1-2):27-44
pubmed: 2378210
N Engl J Med. 2020 Oct 8;383(15):1483-1488
pubmed: 32706956
Int Health. 2018 Mar 1;10(suppl_1):i40-i48
pubmed: 29471342
Ann Trop Med Parasitol. 2002 Mar;96 Suppl 1:S93-104
pubmed: 12081254
Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):809-26
pubmed: 10365406
Tropenmed Parasitol. 1978 Mar;29(1):51-4
pubmed: 205977
PLoS One. 2014 Dec 29;9(12):e115886
pubmed: 25545677
Parasit Vectors. 2016 Nov 14;9(1):581
pubmed: 27842567
Int Health. 2016 Mar;8(2):116-23
pubmed: 26152231
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):13-28
pubmed: 21321478
Clin Infect Dis. 2007 Jan 1;44(1):53-60
pubmed: 17143815
Clin Infect Dis. 2017 Nov 29;65(12):2026-2034
pubmed: 29020189
Tropenmed Parasitol. 1984 Sep;35(3):163-6
pubmed: 6541822
Parasit Vectors. 2015 Apr 02;8:202
pubmed: 25886166
Bull World Health Organ. 1979;57(4):655-62
pubmed: 316743
Am J Trop Med Hyg. 1991 Jul;45(1):132-7
pubmed: 1867345
PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2169
pubmed: 23634234
Parasit Vectors. 2020 Oct 16;13(1):519
pubmed: 33066826
PLoS Negl Trop Dis. 2019 Dec 5;13(12):e0007557
pubmed: 31805049
Med Trop (Mars). 2005;65(1):69-79
pubmed: 15903082
Acta Trop. 1991 Feb;48(4):271-84
pubmed: 1674401
Am J Trop Med Hyg. 2004 Nov;71(5):602-7
pubmed: 15569792